Scripps Research Logo
Law Lab banner photo

The Law Laboratory

Publications

Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33. Kong L, Giang E, Nieusma T, Robbins JB, Deller MC, Stanfield RL, Wilson IA, Law M. J Virol. 2012 Dec;86(23):13085-8.

Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host. Brown RJ, Hudson N, Wilson G, Rehman SU, Jabbari S, Hu K, Tarr AW, Borrow P, Joyce M, Lewis J, Zhu LF, Law M, Kneteman N, Tyrrell DL, McKeating JA, Ball JK. J Virol. 2012 Nov;86(22):11956-66.

A meta-analysis of the existing knowledge of immunoreactivity against hepatitis C virus (HCV). Kim Y, Vaughan K, Greenbaum J, Peters B, Law M, Sette A. PLoS One. 2012;7(5):e38028.

Chronic hepatitis C virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells. Roughan JE, Reardon KM, Cogburn KE, Quendler H, Pockros PJ, Law M. Clin Vaccine Immunol. 2012 Jul;19(7):1027-37.

Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Kong L, Giang E, Robbins JB, Stanfield RL, Burton DR, Wilson IA, Law M. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9499-504.

Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, Rice CM, Ploss A, Burton DR, Law M. Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6205-10.

Self-assembling peptide nanotubes with antiviral activity against hepatitis C virus. Montero A, Gastaminza P, Law M, Cheng G, Chisari FV, Ghadiri MR. Chem Biol. 2011 Nov 23;18(11):1453-62.

A genetically humanized mouse model for hepatitis C virus infection. Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, Jones CT, Schoggins JW, Catanese MT, Burton DR, Law M, Rice CM, Ploss A. Nature. 2011 Jun 8;474(7350):208-11.

Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. Gastaminza P, Dryden KA, Boyd B, Wood MR, Law M, Yeager M, Chisari FV. J Virol. 2010 Nov;84(21):10999-1009.

Acidic residues in the membrane-proximal stalk region of vaccinia virus protein B5 are required for glycosaminoglycan-mediated disruption of the extracellular enveloped virus outer membrane. Roberts KL, Breiman A, Carter GC, Ewles HA, Hollinshead M, Law M, Smith GL. J Gen Virol. 2009 Jul;90(Pt 7):1582-91.

Antibodies against viruses: passive and active immunization. Law M, Hangartner L. Curr Opin Immunol. 2008 Aug;20(4):486-92.

Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR. Nat Med. 2008 Jan;14(1):25-7.

Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. Law M, Cardoso RM, Wilson IA, Burton DR. J Virol. 2007 Apr;81(8):4272-85.

Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Pütz MM, Midgley CM, Law M, Smith GL.Nat Med. 2006 Nov;12(11):1310-5.

Ligand-induced and nonfusogenic dissolution of a viral membrane. Law M, Carter GC, Roberts KL, Hollinshead M, Smith GL. Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5989-94.

Comparing antigenicity and immunogenicity of engineered gp120. Selvarajah S, Puffer B, Pantophlet R, Law M, Doms RW, Burton DR. J Virol. 2005 Oct;79(19):12148-63.

Entry of the vaccinia virus intracellular mature virion and its interactions with glycosaminoglycans.Carter GC, Law M, Hollinshead M, Smith GL. J Gen Virol. 2005 May;86(Pt 5):1279-90.

An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. Law M, Pütz MM, Smith GL. J Gen Virol. 2005 Apr;86(Pt 4):991-1000. The exit of vaccinia virus from infected cells. Smith GL, Law M. Virus Res. 2004 Dec;106(2):189-97.

Studying the binding and entry of the intracellular and extracellular enveloped forms of vaccinia virus. Law M, Smith GL. Methods Mol Biol. 2004;269:187-204.

Yaba-like disease virus protein Y144R, a member of the complement control protein family, is present on enveloped virions that are associated with virus-induced actin tails. Law M, Hollinshead M, Lee HJ, Smith GL. J Gen Virol. 2004 May;85(Pt 5):1279-90.

Vaccinia virus motility. Smith GL, Murphy BJ, Law M. Annu Rev Microbiol. 2003;57:323-42.

Vaccinia virus cores are transported on microtubules. Carter GC, Rodger G, Murphy BJ, Law M, Krauss O, Hollinshead M, Smith GL. J Gen Virol. 2003 Sep;84(Pt 9):2443-58.

The formation and function of extracellular enveloped vaccinia virus. Smith GL, Vanderplasschen A, Law M. J Gen Virol. 2002 Dec;83(Pt 12):2915-31.

Antibody-sensitive and antibody-resistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibody-resistant spread. Law M, Hollinshead R, Smith GL. J Gen Virol. 2002 Jan;83(Pt 1):209-22. Erratum in: J Gen Virol 2002 May;83(Pt 5):1251.